JAK inhibition as a therapeutic strategy for immune and inflammatory diseases

[1]  J. Chen,et al.  349 - BMS-986165 is a Highly Potent and Selective Allosteric Inhibitor of TYK2, Blocks Il-12, IL-23 and type I Interferon Signaling and Provides for Robust Efficacy in Preclinical Models of Inflammatory Bowel Disease , 2018 .

[2]  D. Furst,et al.  A Case Series on Patients on Tofacitinib in Combination With a Biologic , 2017, Journal of clinical rheumatology.

[3]  D. Solomon,et al.  Incidence and Prevalence of Cardiovascular Risk Factors Among Patients With Rheumatoid Arthritis, Psoriasis, or Psoriatic Arthritis , 2017, Arthritis care & research.

[4]  Yoshiya Tanaka,et al.  Herpes Zoster and Tofacitinib: Clinical Outcomes and the Risk of Concomitant Therapy , 2017, Arthritis & rheumatology.

[5]  Elie Needle,et al.  The Safety and Immunogenicity of Live Zoster Vaccination in Patients With Rheumatoid Arthritis Before Starting Tofacitinib: A Randomized Phase II Trial , 2017, Arthritis & rheumatology.

[6]  A. Kheirkhah,et al.  A Pilot Randomized Trial on Safety and Efficacy of a Novel Topical Combined Inhibitor of Janus Kinase 1/3 and Spleen Tyrosine Kinase for GVHD-Associated Ocular Surface Disease , 2017, Cornea.

[7]  M. Genovese,et al.  Peficitinib, a JAK Inhibitor, in Combination With Limited Conventional Synthetic Disease‐Modifying Antirheumatic Drugs in the Treatment of Moderate‐to‐Severe Rheumatoid Arthritis , 2017, Arthritis & rheumatology.

[8]  K. Winthrop.  The emerging safety profile of JAK inhibitors in rheumatic disease , 2017, Nature Reviews Rheumatology.

[9]  T. Waldmann,et al.  Disorders of the JAK/STAT Pathway in T Cell Lymphoma Pathogenesis: Implications for Immunotherapy. , 2017, Annual review of immunology.

[10]  G. D'Haens,et al.  Safety and Efficacy of ABT-494 (Upadacitinib), an Oral Jak1 Inhibitor, as Induction Therapy in Patients with Crohn's Disease: Results from Celest , 2017 .

[11]  B. King,et al.  Treatment of Hypereosinophilic Syndrome with Cutaneous Involvement with the JAK Inhibitors Tofacitinib and Ruxolitinib. , 2017, The Journal of investigative dermatology.

[12]  M. Genovese,et al.  Peficitinib, a JAK Inhibitor, in the Treatment of Moderate‐to‐Severe Rheumatoid Arthritis in Patients With an Inadequate Response to Methotrexate , 2017, Arthritis & rheumatology.

[13]  J. Smolen,et al.  Brief Report: Remission Rates With Tofacitinib Treatment in Rheumatoid Arthritis: A Comparison of Various Remission Criteria , 2017, Arthritis & rheumatology.

[14]  D. M. van der Heijde,et al.  Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease‐Modifying Antirheumatic Drug Treatment , 2017, Arthritis & rheumatology.

[15]  S. Vermeire,et al.  Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials , 2017, Gut.

[16]  D. M. van der Heijde,et al.  Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis , 2017, The New England journal of medicine.

[17]  S. Cohen,et al.  Malignancy and Janus Kinase Inhibition. , 2017, Rheumatic diseases clinics of North America.

[18]  L. Christopher‐Stine,et al.  A case of refractory dermatomyositis responsive to tofacitinib. , 2017, Seminars in arthritis and rheumatism.

[19]  C. Ensor,et al.  Janus kinase inhibition for immunosuppression in solid organ transplantation: Is there a role in complex immunologic challenges? , 2017, Human immunology.

[20]  N. Grimster,et al.  Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1 , 2017, Expert opinion on therapeutic patents.

[21]  N. Grimster,et al.  Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2 , 2017, Expert opinion on therapeutic patents.

[22]  M. Erlacher,et al.  Impact of tofacitinib treatment on human B-cells in vitro and in vivo. , 2017, Journal of autoimmunity.

[23]  J. O’Shea,et al.  Tofacitinib Ameliorates Murine Lupus and Its Associated Vascular Dysfunction , 2017, Arthritis & rheumatology.

[24]  M. Dougados,et al.  Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study , 2016, Annals of the rheumatic diseases.

[25]  D. M. van der Heijde,et al.  Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study , 2016, Annals of the rheumatic diseases.

[26]  Андрей Юрьевич Барановский.  Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial (статья) , 2017 .

[27]  R. Chapin,et al.  Effects of the Janus Kinase Inhibitor, Tofacitinib, on Testicular Leydig Cell Hyperplasia and Adenoma in Rats, and on Prolactin Signaling in Cultured Primary Rat Leydig Cells , 2017, Toxicological sciences : an official journal of the Society of Toxicology.

[28]  W. Sandborn,et al.  Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis. , 2017, The New England journal of medicine.

[29]  B. King,et al.  Tofacitinib for the treatment of alopecia areata and variants in adolescents , 2017, Journal of the American Academy of Dermatology.

[30]  B. King,et al.  Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients , 2017, Journal of the American Academy of Dermatology.

[31]  K. Kabashima,et al.  JAK inhibitor JTE-052 regulates contact hypersensitivity by downmodulating T cell activation and differentiation. , 2016, Journal of dermatological science (Amsterdam).

[32]  Hanlin L. Wang,et al.  Tofacitinib Response in Juvenile Idiopathic Arthritis (JIA) and Collagenous Colitis. , 2016, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.

[33]  M. González-Gay,et al.  Cardiovascular safety findings in patients with rheumatoid arthritis treated with tofacitinib, an oral Janus kinase inhibitor. , 2016, Seminars in arthritis and rheumatism.

[34]  M. Scheinberg,et al.  Reversal of Alopecia Universalis by Tofacitinib: A Case Report , 2016, Annals of Internal Medicine.

[35]  J. Bauman,et al.  Discovery of a JAK3-Selective Inhibitor: Functional Differentiation of JAK3-Selective Inhibition over pan-JAK or JAK1-Selective Inhibition. , 2016, ACS chemical biology.

[36]  M. Gooderham,et al.  Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial , 2016, The British journal of dermatology.

[37]  B. King,et al.  Idiopathic erythema multiforme: Evidence of underlying Janus kinase–signal transducer and activator of transcription activation and successful treatment with tofacitinib , 2016, JAAD case reports.

[38]  B. Strober,et al.  Effects of tofacitinib on cardiovascular risk factors and cardiovascular outcomes based on phase III and long-term extension data in patients with plaque psoriasis. , 2016, Journal of the American Academy of Dermatology.

[39]  J. Kushner,et al.  Extended‐Release Once‐Daily Formulation of Tofacitinib: Evaluation of Pharmacokinetics Compared With Immediate‐Release Tofacitinib and Impact of Food , 2016, Journal of clinical pharmacology.

[40]  K. Ichinose,et al.  Successful treatment of palmoplantar pustulosis with rheumatoid arthritis, with tofacitinib: Impact of this JAK inhibitor on T-cell differentiation. , 2016, Clinical immunology.

[41]  S. Feldman,et al.  Treatment of plaque psoriasis with an ointment formulation of the Janus kinase inhibitor, tofacitinib: a Phase 2b randomized clinical trial , 2016, BMC Dermatology.

[42]  M. Steinhoff,et al.  Molecular mechanisms of pruritus. , 2016, Current research in translational medicine.

[43]  E. Bateman,et al.  Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials. , 2016, The Lancet. Respiratory medicine.

[44]  D. M. van der Heijde,et al.  Is radiographic progression in modern rheumatoid arthritis trials still a robust outcome? Experience from tofacitinib clinical trials , 2016, Arthritis Research & Therapy.

[45]  J. Ko,et al.  Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata. , 2016, JCI insight.

[46]  P. Hawkins,et al.  Phosphoproteomic Analyses of Interleukin 2 Signaling Reveal Integrated JAK Kinase-Dependent and -Independent Networks in CD8+ T Cells , 2016, Immunity.

[47]  V. Strand,et al.  Tofacitinib versus methotrexate in rheumatoid arthritis: patient-reported outcomes from the randomised phase III ORAL Start trial , 2016, RMD Open.

[48]  B. Engelhardt,et al.  Current multiple sclerosis treatments have improved our understanding of MS autoimmune pathogenesis , 2016, European journal of immunology.

[49]  S. Shen-Orr,et al.  Tofacitinib for polyarteritis nodosa: a tailored therapy , 2016, Annals of the rheumatic diseases.

[50]  S. Mostafavi,et al.  Network pharmacology of JAK inhibitors , 2016, Proceedings of the National Academy of Sciences.

[51]  M. González-Gay,et al.  Effects of tofacitinib and other DMARDs on lipid profiles in rheumatoid arthritis: implications for the rheumatologist. , 2016, Seminars in arthritis and rheumatism.

[52]  W. Abramovits,et al.  Efficacy of tofacitinib in treatment of alopecia universalis in two patients , 2016, Journal of the European Academy of Dermatology and Venereology : JEADV.

[53]  J. Merola,et al.  Tofacitinib Citrate for Refractory Cutaneous Dermatomyositis: An Alternative Treatment. , 2016, JAMA dermatology.

[54]  E. Latz,et al.  Long-term activation of the innate immune system in atherosclerosis. , 2016, Seminars in immunology.

[55]  J. Kremer,et al.  Efficacy and safety of tofacitinib in patients with active rheumatoid arthritis: review of key Phase 2 studies , 2016, International journal of rheumatic diseases.

[56]  M. Genovese,et al.  Efficacy and Safety of ABT‐494, a Selective JAK‐1 Inhibitor, in a Phase IIb Study in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate , 2016, Arthritis & Rheumatology.

[57]  J. Kremer,et al.  A Phase IIb Study of ABT‐494, a Selective JAK‐1 Inhibitor, in Patients With Rheumatoid Arthritis and an Inadequate Response to Anti–Tumor Necrosis Factor Therapy , 2016, Arthritis & rheumatology.

[58]  E. R. Sutherland,et al.  Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial , 2016, The Lancet.

[59]  T. Huizinga,et al.  Efficacy of tofacitinib monotherapy in methotrexate-naive patients with early or established rheumatoid arthritis , 2016, RMD Open.

[60]  A. Anisfeld,et al.  THU0199 Tofacitinib, An Oral Janus Kinase Inhibitor, in The Treatment of Rheumatoid Arthritis: Changes in Lymphocytes and Lymphocyte Subset Counts and Reversibility after Up To 8 Years of Tofacitinib Treatment , 2016 .

[61]  K. Papp,et al.  A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate‐to‐severe psoriasis , 2016, The British journal of dermatology.

[62]  J. Devenport,et al.  Relationship Between Baseline and Early Changes in C‐Reactive Protein and Interleukin‐6 Levels and Clinical Response to Tocilizumab in Rheumatoid Arthritis , 2016, Arthritis care & research.

[63]  P. Tugwell,et al.  Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysis. , 2016, The Cochrane database of systematic reviews.

[64]  H. Bluyssen,et al.  Targeted inhibition of STATs and IRFs as a potential treatment strategy in cardiovascular disease , 2016, Oncotarget.

[65]  R. P. Maguire,et al.  Activity of secukinumab, an anti-IL-17A antibody, on brain lesions in RRMS: results from a randomized, proof-of-concept study , 2016, Journal of Neurology.

[66]  K. Reich,et al.  Investigation of selective JAK1 inhibitor GSK2586184 for the treatment of psoriasis in a randomized placebo‐controlled phase IIa study , 2016, The British journal of dermatology.

[67]  S. Bernatsky,et al.  Brief Report: Risk of Gastrointestinal Perforation Among Rheumatoid Arthritis Patients Receiving Tofacitinib, Tocilizumab, or Other Biologic Treatments , 2016, Arthritis & rheumatology.

[68]  L. French,et al.  Transient Efficacy of Tofacitinib in Alopecia Areata Universalis , 2016, Case Reports in Dermatology.

[69]  T. Fingerlin,et al.  Beryllium-induced lung disease exhibits expression profiles similar to sarcoidosis , 2016, European Respiratory Journal.

[70]  M. Genovese,et al.  Efficacy of VX-509 (decernotinib) in combination with a disease-modifying antirheumatic drug in patients with rheumatoid arthritis: clinical and MRI findings , 2016, Annals of the rheumatic diseases.

[71]  E. Hachulla,et al.  Safety, tolerability, efficacy and pharmacodynamics of the selective JAK1 inhibitor GSK2586184 in patients with systemic lupus erythematosus , 2016, Lupus.

[72]  J. D. Clark,et al.  Tofacitinib attenuates pathologic immune pathways in patients with psoriasis: A randomized phase 2 study. , 2016, The Journal of allergy and clinical immunology.

[73]  B. King,et al.  Topical Ruxolitinib for the Treatment of Alopecia Universalis. , 2016, JAMA dermatology.

[74]  J. Kremer,et al.  Baricitinib in Patients with Refractory Rheumatoid Arthritis. , 2016, The New England journal of medicine.

[75]  J. Taunton,et al.  Essential biphasic role for JAK3 catalytic activity in IL-2 receptor signaling , 2016, Nature chemical biology.

[76]  H. Yamanaka,et al.  Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study , 2016, Arthritis Research & Therapy.

[77]  B. Wyman,et al.  Comparing the effects of tofacitinib, methotrexate and the combination, on bone marrow oedema, synovitis and bone erosion in methotrexate-naive, early active rheumatoid arthritis: results of an exploratory randomised MRI study incorporating semiquantitative and quantitative techniques , 2016, Annals of the rheumatic diseases.

[78]  J. Duarte.  Spondyloarthropathies: IL-17A blockade ameliorates ankylosing spondylitis , 2016, Nature Reviews Rheumatology.

[79]  Charles King,et al.  2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis , 2016, Arthritis & rheumatology.

[80]  M. Genovese,et al.  VX‐509 (Decernotinib), an Oral Selective JAK‐3 Inhibitor, in Combination With Methotrexate in Patients With Rheumatoid Arthritis , 2016, Arthritis & rheumatology.

[81]  K. Liao,et al.  Cardiovascular risk factor management in patients with RA compared to matched non-RA patients , 2015, Rheumatology.

[82]  M. Iwasaki,et al.  Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study , 2015, Annals of the rheumatic diseases.

[83]  D. Veale,et al.  Tofacitinib regulates synovial inflammation in psoriatic arthritis, inhibiting STAT activation and induction of negative feedback inhibitors , 2015, Annals of the rheumatic diseases.

[84]  C. Zerbini,et al.  Efficacy and safety of tofacitinib following inadequate response to conventional synthetic or biological disease-modifying antirheumatic drugs , 2015, Annals of the rheumatic diseases.

[85]  E. Lee,et al.  The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis , 2015, Annals of the rheumatic diseases.

[86]  P. Rutgeerts,et al.  Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease. , 2016, The New England journal of medicine.

[87]  George D. Kalliolias,et al.  TNF biology, pathogenic mechanisms and emerging therapeutic strategies , 2016, Nature Reviews Rheumatology.

[88]  Massimo Gadina,et al.  Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases , 2016, Nature Reviews Rheumatology.

[89]  G. Schett,et al.  Interleukin-1 function and role in rheumatic disease , 2016, Nature Reviews Rheumatology.

[90]  B. Elewski,et al.  Anti-IL-17 Medications Used in the Treatment of Plaque Psoriasis and Psoriatic Arthritis: A Comprehensive Review , 2016, American Journal of Clinical Dermatology.

[91]  J. French,et al.  Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials , 2015, Arthritis Research & Therapy.

[92]  J. Kremer,et al.  Effects of tofacitinib monotherapy on patient-reported outcomes in a randomized phase 3 study of patients with active rheumatoid arthritis and inadequate responses to DMARDs , 2015, Arthritis Research & Therapy.

[93]  B. King,et al.  Tofacitinib Citrate for the Treatment of Vitiligo: A Pathogenesis-Directed Therapy. , 2015, JAMA dermatology.

[94]  A. Gottlieb,et al.  Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo‐controlled, phase III trials , 2015, The British journal of dermatology.

[95]  A. Gottlieb,et al.  Downmodulation of key inflammatory cell markers with a topical Janus kinase 1/2 inhibitor , 2015, The British journal of dermatology.

[96]  S. Paul,et al.  Preliminary response to Janus kinase inhibition with baricitinib in chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperatures (CANDLE) , 2015, Pediatric Rheumatology.

[97]  F. Salituro,et al.  Discovery of VX-509 (Decernotinib): A Potent and Selective Janus Kinase 3 Inhibitor for the Treatment of Autoimmune Diseases. , 2015, Journal of medicinal chemistry.

[98]  J. Shapiro,et al.  The role of lymphocytes in the development and treatment of alopecia areata , 2015, Expert review of clinical immunology.

[99]  T. Dainichi,et al.  The Janus kinase inhibitor JTE-052 improves skin barrier function through suppressing signal transducer and activator of transcription 3 signaling. , 2015, The Journal of allergy and clinical immunology.

[100]  K. Papp,et al.  A phase 2a randomized, double‐blind, placebo‐controlled, sequential dose‐escalation study to evaluate the efficacy and safety of ASP015K, a novel Janus kinase inhibitor, in patients with moderate‐to‐severe psoriasis , 2015, The British journal of dermatology.

[101]  S. Chimenti,et al.  Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial , 2015, The Lancet.

[102]  Jiayin Huang,et al.  SAT0227 The Effect of Deuteration of VX-509 (Decernotinib) on Drug-Drug Interactions (DDI) with Midazolam , 2015 .

[103]  G. Russ,et al.  Evaluation of the Effect of Tofacitinib Exposure on Outcomes in Kidney Transplant Patients , 2015, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[104]  M. Hochberg,et al.  Disease Activity in Rheumatoid Arthritis and the Risk of Cardiovascular Events , 2015, Arthritis & rheumatology.

[105]  Mee Shelley,et al.  Identification of highly potent and selective Tyk2 inhibitors for the treatment of autoimmune diseases through structure-based drug design (THER2P.961) , 2015 .

[106]  L. Iversen,et al.  Tofacitinib withdrawal and retreatment in moderate‐to‐severe chronic plaque psoriasis: a randomized controlled trial , 2015, The British journal of dermatology.

[107]  I. Pavord,et al.  Mepolizumab treatment in patients with severe eosinophilic asthma. , 2015, The New England journal of medicine.

[108]  M. V. D. van den Brink,et al.  Interleukin-22: immunobiology and pathology. , 2015, Annual review of immunology.

[109]  J. Kremer,et al.  Evaluation of the effect of tofacitinib on measured glomerular filtration rate in patients with active rheumatoid arthritis: results from a randomised controlled trial , 2015, Arthritis Research & Therapy.

[110]  V. Strand,et al.  Tofacitinib With Methotrexate in Third‐Line Treatment of Patients With Active Rheumatoid Arthritis: Patient‐Reported Outcomes From a Phase III Trial , 2015, Arthritis care & research.

[111]  S. Chimenti,et al.  Tofacitinib for the treatment of moderate-to-severe psoriasis , 2015, Expert review of clinical immunology.

[112]  A. Christiano,et al.  Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib , 2015, EBioMedicine.

[113]  M. Milad,et al.  Potential Mechanisms Leading to the Abnormal Lipid Profile in Patients With Rheumatoid Arthritis Versus Healthy Volunteers and Reversal by Tofacitinib†, ‡ , 2015, Arthritis & rheumatology.

[114]  N. Sattar,et al.  An Evaluation of Risk Factors for Major Adverse Cardiovascular Events During Tocilizumab Therapy , 2015, Arthritis & rheumatology.

[115]  R. Fleischmann,et al.  A Randomized, Double‐Blind, Placebo‐Controlled, Twelve‐Week, Dose‐Ranging Study of Decernotinib, an Oral Selective JAK‐3 Inhibitor, as Monotherapy in Patients With Active Rheumatoid Arthritis , 2015, Arthritis & rheumatology.

[116]  Massimo Gadina,et al.  The JAK-STAT pathway: impact on human disease and therapeutic intervention. , 2015, Annual review of medicine.

[117]  P. Guglielmelli,et al.  Ruxolitinib‐induced reversal of alopecia universalis in a patient with essential thrombocythemia , 2015, American journal of hematology.

[118]  L. Carmona,et al.  Lipid Profile Changes in Patients With Chronic Inflammatory Arthritis Treated With Biologic Agents and Tofacitinib in Randomized Clinical Trials: A Systematic Review and Meta‐Analysis , 2015, Arthritis & rheumatology.

[119]  Stephen C. J. Parker,et al.  Stretch-Enhancers Delineate Disease-Associated Regulatory Nodes in T Cells , 2014, Nature.

[120]  M. Weinblatt,et al.  Baricitinib Versus Placebo or Adalimumab in Patients with Active Rheumatoid Arthritis (RA) and an Inadequate Response to Background Methotrexate Therapy: Results of a Phase 3 Study , 2015 .

[121]  Raveendhara R. Bannuru,et al.  American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis , 2015 .

[122]  Christopher M Harris,et al.  Tricyclic Covalent Inhibitors Selectively Target Jak3 through an Active Site Thiol* , 2014, The Journal of Biological Chemistry.

[123]  T. Bieber,et al.  Remission of recalcitrant dermatomyositis treated with ruxolitinib. , 2014, The New England journal of medicine.

[124]  P. Scherle,et al.  The pharmacokinetics, pharmacodynamics, and safety of baricitinib, an oral JAK 1/2 inhibitor, in healthy volunteers , 2014, Journal of clinical pharmacology.

[125]  S. Rutz,et al.  The IL-20 subfamily of cytokines — from host defence to tissue homeostasis , 2014, Nature Reviews Immunology.

[126]  Stefan Rose-John,et al.  IL-6 biology: implications for clinical targeting in rheumatic disease , 2014, Nature Reviews Rheumatology.

[127]  A. Betz,et al.  The Novel Kinase Inhibitor PRT062070 (Cerdulatinib) Demonstrates Efficacy in Models of Autoimmunity and B-Cell Cancer , 2014, The Journal of Pharmacology and Experimental Therapeutics.

[128]  L. Nelles,et al.  Triazolopyridines as selective JAK1 inhibitors: from hit identification to GLPG0634. , 2014, Journal of medicinal chemistry.

[129]  D. Fabbro,et al.  Advances in kinase targeting: current clinical use and clinical trials. , 2014, Trends in pharmacological sciences.

[130]  E. Jacobsen,et al.  Ibrutinib for the Treatment of Mantle Cell Lymphoma , 2014, Clinical Cancer Research.

[131]  P. Stein,et al.  Inhibition of TYK2 and JAK1 Ameliorates Imiquimod-Induced Psoriasis-like Dermatitis by Inhibiting IL-22 and the IL-23/IL-17 Axis , 2014, The Journal of Immunology.

[132]  W. Sandborn,et al.  A phase 2 study of tofacitinib, an oral Janus kinase inhibitor, in patients with Crohn's disease. , 2014, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[133]  A. Christiano,et al.  Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition , 2014, Nature Medicine.

[134]  J. Isaacs,et al.  Changes in serum creatinine in patients with active rheumatoid arthritis treated with tofacitinib: results from clinical trials , 2014, Arthritis Research & Therapy.

[135]  F. Rosenbauer,et al.  TH9 cells that express the transcription factor PU.1 drive T cell–mediated colitis via IL-9 receptor signaling in intestinal epithelial cells , 2014, Nature Immunology.

[136]  A. Hartmann,et al.  IL-9 and its receptor are predominantly involved in the pathogenesis of UC , 2014, Gut.

[137]  L. Olson,et al.  THU0127 Pharmacodynamics of A Novel JAK1 Selective Inhibitor in Rat Arthritis and Anemia Models and in Healthy Human Subjects , 2014 .

[138]  M. Eck,et al.  JAK–cytokine receptor recognition, unboxed , 2014, Nature Structural &Molecular Biology.

[139]  E. Lee,et al.  Safety and Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, for the Treatment of Rheumatoid Arthritis in Open-label, Longterm Extension Studies , 2014, The Journal of Rheumatology.

[140]  A. Gonzales,et al.  Oclacitinib (APOQUEL®) is a novel Janus kinase inhibitor with activity against cytokines involved in allergy , 2014, Journal of veterinary pharmacology and therapeutics.

[141]  J. Scheller,et al.  Interleukin-6: from basic biology to selective blockade of pro-inflammatory activities. , 2014, Seminars in immunology.

[142]  Mark E Flanagan,et al.  Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases. , 2014, Journal of medicinal chemistry.

[143]  N. Okiyama,et al.  Reversal of CD8 T-Cell–Mediated Mucocutaneous Graft-Versus-Host-Like Disease by the JAK Inhibitor Tofacitinib , 2013, The Journal of investigative dermatology.

[144]  R. V. van Vollenhoven,et al.  Tofacitinib versus methotrexate in rheumatoid arthritis. , 2014, The New England journal of medicine.

[145]  C. Klein,et al.  Interleukin 10 receptor signaling: master regulator of intestinal mucosal homeostasis in mice and humans. , 2014, Advances in immunology.

[146]  P. Loke,et al.  IL-22-producing CD4+ cells are depleted in actively inflamed colitis tissue , 2013, Mucosal Immunology.

[147]  N. Yawalkar,et al.  Cytokines and Chemokines in Irritant Contact Dermatitis , 2013, Mediators of inflammation.

[148]  J. Tena,et al.  A blinded, randomized, placebo‐controlled trial of the efficacy and safety of the Janus kinase inhibitor oclacitinib (Apoquel®) in client‐owned dogs with atopic dermatitis , 2013, Veterinary dermatology.

[149]  Kenneth K C Man,et al.  Efficacy and safety of tofacitinib in the treatment of rheumatoid arthritis: a systematic review and meta-analysis , 2013, BMC Musculoskeletal Disorders.

[150]  L. Nelles,et al.  Preclinical Characterization of GLPG0634, a Selective Inhibitor of JAK1, for the Treatment of Inflammatory Diseases , 2013, The Journal of Immunology.

[151]  Kristin Stephens,et al.  Vedolizumab as induction and maintenance therapy for Crohn's disease. , 2013, The New England journal of medicine.

[152]  John D Isaacs,et al.  Tofacitinib in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis , 2013, Annals of Internal Medicine.

[153]  D. Milojković,et al.  Progressive multifocal leukoencephalopathy associated with ruxolitinib. , 2013, The New England journal of medicine.

[154]  B. Wyman,et al.  Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study. , 2013, Arthritis and rheumatism.

[155]  Tamas Koncz,et al.  Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial , 2013, The Lancet.

[156]  Steven M Holland,et al.  JAKs and STATs in immunity, immunodeficiency, and cancer. , 2013, The New England journal of medicine.

[157]  Kate Traynor,et al.  FDA approves tofacitinib for rheumatoid arthritis. , 2012, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[158]  J. Wood,et al.  SB1578, a Novel Inhibitor of JAK2, FLT3, and c-Fms for the Treatment of Rheumatoid Arthritis , 2012, The Journal of Immunology.

[159]  E. Lee,et al.  Radiographic, Clinical and Functional Comparison of Tofacitinib Monotherapy Versus Methotrexate in Methotrexate-naïve Patients with Rheumatoid Arthritis.: 2486 , 2012 .

[160]  A. Gottlieb,et al.  Preliminary clinical activity of a topical JAK1/2 inhibitor in the treatment of psoriasis. , 2012, Journal of the American Academy of Dermatology.

[161]  J. Friedewald,et al.  Randomized Phase 2b Trial of Tofacitinib (CP‐690,550) in De Novo Kidney Transplant Patients: Efficacy, Renal Function and Safety at 1 Year , 2012, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[162]  J. Kremer,et al.  Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. , 2012, The New England journal of medicine.

[163]  E. Lee,et al.  Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. , 2012, The New England journal of medicine.

[164]  Min Zhang,et al.  Tofacitinib (CP-690,550), a Janus kinase inhibitor for dry eye disease: results from a phase 1/2 trial. , 2012, Ophthalmology.

[165]  K. Wood,et al.  Regulatory immune cells in transplantation , 2012, Nature Reviews Immunology.

[166]  Marc Vandemeulebroecke,et al.  Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial , 2012, Gut.

[167]  J. Wood,et al.  Discovery of the macrocycle (9E)-15-(2-(pyrrolidin-1-yl)ethoxy)-7,12,25-trioxa-19,21,24-triaza-tetracyclo[18.3.1.1(2,5).1(14,18)]hexacosa-1(24),2,4,9,14(26),15,17,20,22-nonaene (SB1578), a potent inhibitor of janus kinase 2/fms-like tyrosine kinase-3 (JAK2/FLT3) for the treatment of rheumatoid arthr , 2012, Journal of medicinal chemistry.

[168]  Jason Gotlib,et al.  A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. , 2012, The New England journal of medicine.

[169]  Francisco Cervantes,et al.  JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. , 2012, The New England journal of medicine.

[170]  D. Hume,et al.  Therapeutic applications of macrophage colony-stimulating factor-1 (CSF-1) and antagonists of CSF-1 receptor (CSF-1R) signaling. , 2012, Blood.

[171]  K. Fink.  Origin and Function of Circulating Plasmablasts during Acute Viral Infections , 2012, Front. Immun..

[172]  V. Shi,et al.  IL-4 regulates chemokine CCL26 in keratinocytes through the Jak1, 2/Stat6 signal transduction pathway: Implication for atopic dermatitis. , 2012, Molecular immunology.

[173]  John J. O’Shea,et al.  Modulation of Innate and Adaptive Immune Responses by Tofacitinib (CP-690,550) , 2011, The Journal of Immunology.

[174]  I. Behrmann,et al.  Jak1 has a dominant role over Jak3 in signal transduction through γc-containing cytokine receptors. , 2011, Chemistry & biology.

[175]  C. Mok,et al.  Prevalence of atherosclerotic risk factors and the metabolic syndrome in patients with chronic inflammatory arthritis , 2011, Arthritis care & research.

[176]  D. Lipka,et al.  FLT3 as a therapeutic target in AML: still challenging after all these years. , 2010, Blood.

[177]  M. Genovese,et al.  An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis. , 2010, The New England journal of medicine.

[178]  D. Veale,et al.  Cardiovascular Disease and Risk Factors in Patients with Psoriasis and Psoriatic Arthritis , 2010, The Journal of Rheumatology.

[179]  Victor L. J. Tybulewicz,et al.  The SYK tyrosine kinase: a crucial player in diverse biological functions , 2010, Nature Reviews Immunology.

[180]  Stampfer,et al.  Systemic lupus erythematosus and the risk of cardiovascular disease: results from the nurses' health study. , 2009, Arthritis and rheumatism.

[181]  Laurent Abel,et al.  Revisiting Crohn's disease as a primary immunodeficiency of macrophages , 2009, The Journal of experimental medicine.

[182]  J. Parkin,et al.  Treatment of patients with the hypereosinophilic syndrome with mepolizumab. , 2008, The New England journal of medicine.

[183]  L. Audoly,et al.  Cartilage preservation by inhibition of Janus kinase 3 in two rodent models of rheumatoid arthritis , 2008, Arthritis research & therapy.

[184]  Mindy I. Davis,et al.  A quantitative analysis of kinase inhibitor selectivity , 2008, Nature Biotechnology.

[185]  W. Mccune,et al.  Interferon-α promotes abnormal vasculogenesis in lupus: a potential pathway for premature atherosclerosis , 2007 .

[186]  Christophe Baudouin,et al.  The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007). , 2007, The ocular surface.

[187]  François Girodon,et al.  The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera. , 2006, Blood.

[188]  P. Changelian,et al.  The Novel JAK‐3 Inhibitor CP‐690550 Is a Potent Immunosuppressive Agent in Various Murine Models , 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[189]  Mark B Pepys,et al.  C-reactive protein: a critical update. , 2003, The Journal of clinical investigation.

[190]  C. Sawyers,et al.  Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. , 2001, The New England journal of medicine.

[191]  M. Eichelbaum,et al.  CYP3A genetics in drug metabolism , 2001, Nature Medicine.

[192]  L. Ferrucci,et al.  Cardiovascular Disease, Interleukin-6, and Risk of Mortality in Older Women: The Women’s Health and Aging Study , 2001, Circulation.

[193]  J. Darnell,et al.  Crystal Structure of a Tyrosine Phosphorylated STAT-1 Dimer Bound to DNA , 1998, Cell.

[194]  T. Hirano,et al.  Involvement of STAT3 in the Granulocyte Colony-stimulating Factor-induced Differentiation of Myeloid Cells* , 1997, The Journal of Biological Chemistry.

[195]  Andrew H. Liu,et al.  MUTATIONS OF Jak-3 GENE IN PATIENTS WITH AUTOSOMAL SEVERE COMBINED IMMUNE DEFICIENCY (SCID) , 1996, Pediatrics.

[196]  W. Leonard,et al.  Mutation of Jak3 in a Patient with SCID: Essential Role of Jak3 in Lymphoid Development , 1995, Science.